Leukemia Clinical Trials in Nashville

Showing 1761-1768 of 1,768 trials

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

NCT00087542

The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis. The secondary objectives are to determine whether ACP-103 will ameliorate psychosis in patients with Parkinson's disease and whether ACP-103 is safe in Parkinson's disease patients taking multiple anti-parkinsonian medications.

HallucinationsPsychosesParkinson's Disease

ACADIA Pharmaceuticals Inc.60 participantsStarted Mar 2004

Fountain Valley, California, United States • Sunnyvale, California, United States • Danbury, Connecticut, United States +10 more locations

UNKNOWNPhase 4110 miles

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

NCT00131313

This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.

Chronic Lymphocytic Leukemia

East Valley Hematology and Oncology Medical Group180 participantsStarted Jan 2003

Muscle Shoals, Alabama, United States • Burbank, California, United States • Concord, California, United States +49 more locations

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Leukemia Trials in Other Cities

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

CP-481,715 Nickel Allergy Study.

Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer

Other Conditions in Nashville